Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 studyAlexander E. Perl, Mark J. Levis, Mark R. Litzow et al.|The Lancet Oncology|2017Cited by 493
Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).Mark J. Levis, Erkut Bahceci, Alexander E. Perl et al.|Journal of Clinical Oncology|2015Cited by 39